A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

NCT04630353 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision.

Conditions

HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer

Interventions

DRUG: HB-201 IV
DRUG: HB-201 IV

Sponsor

Hookipa Biotech GmbH